Amyris (NASDAQ:AMRS) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Amyris (NASDAQ:AMRSGet Rating) from a strong sell rating to a hold rating in a report published on Tuesday, reports.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

Separately, began coverage on shares of Amyris in a report on Thursday, March 31st. They issued a sell rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Based on data from, the stock currently has an average rating of Buy and an average target price of $19.17.

Shares of AMRS stock opened at $3.69 on Tuesday. The company has a quick ratio of 2.09, a current ratio of 2.37 and a debt-to-equity ratio of 1.26. Amyris has a 52 week low of $3.22 and a 52 week high of $17.42. The stock has a market capitalization of $1.17 billion, a PE ratio of -1.90 and a beta of 1.63. The firm has a 50 day moving average of $4.32 and a two-hundred day moving average of $5.96.

Amyris (NASDAQ:AMRSGet Rating) last announced its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.23). The firm had revenue of $64.80 million for the quarter, compared to analyst estimates of $54.63 million. During the same quarter last year, the firm earned ($0.44) EPS. The company’s quarterly revenue was down 18.7% on a year-over-year basis. Analysts expect that Amyris will post -0.73 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in AMRS. Morgan Stanley raised its stake in Amyris by 17.2% during the 2nd quarter. Morgan Stanley now owns 478,581 shares of the biotechnology company’s stock worth $7,834,000 after acquiring an additional 70,223 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in Amyris during the 3rd quarter worth $141,000. SG Americas Securities LLC acquired a new stake in Amyris during the 3rd quarter worth $1,332,000. Victory Capital Management Inc. raised its stake in Amyris by 71.5% during the 3rd quarter. Victory Capital Management Inc. now owns 282,552 shares of the biotechnology company’s stock worth $3,880,000 after acquiring an additional 117,769 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Amyris in the third quarter valued at $208,000. Hedge funds and other institutional investors own 49.43% of the company’s stock.

About Amyris (Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Further Reading

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with's FREE daily email newsletter.